2005 issue 1


Volume 21, issue 1


Immunosupressive drugs and MS - returning to the past

Wojciech Wicha1, Jacek Zaborski1
1. II Klinika Neurologiczna Instytutu Psychiatrii i Neurologii w Warszawie
Farmakoterapia w Psychiatrii i Neurologii, 2005, 1, 33-41
Keywords: multiple sclerosis, disease-modifying drugs, chemotherapeutic agents


Due to high prevalence multiple sclerosis is a common neurological disorder and major young adults disability cause. Despite great expectations following interferon beta and glatiramer acetate development, there is no evidence for a significant break-up in MS treatment. Furthermore, some clinical trials results seem to be dubious. For these reasons chemotherapeutic agents such as azathioprine, cyclophosphamide, cladribine, methotrexate and mitoxantrone are currently reviewed as disease modifying drugs.